President Donald Trump just dropped a bombshell that could save Americans billions on prescription drugs.
According to Breitbart, on Friday, December 19, 2025, Trump unveiled groundbreaking most-favored-nation (MFN) deals with nine additional pharmaceutical giants, bringing the total to 14 agreements since late September, all aimed at slashing drug costs to match the lowest global prices and offering steep discounts via the Trump Rx website.
For retirees on fixed incomes, this is a lifeline—medications like Gilead Sciences’ Hepatitis C treatment Epclusa will plummet from $24,920 to just $2,425, easing a crushing financial burden that’s forced many to ration life-saving care. From a conservative standpoint, it’s high time Big Pharma stopped gouging Americans, who account for just 4% of the global population but fuel 75% of their profits. Let’s keep the spotlight on these deals and ensure no company dodges accountability.
The latest agreements include heavyweights like Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi. These join earlier pacts with Pfizer, Eli Lilly, Novo Nordisk, AstraZeneca, and EMD Serono, starting with Pfizer months ago.
Announced in the Roosevelt Room, these deals cover drugs for asthma, cancers, HIV, multiple sclerosis, and more, with MFN pricing accessible to all State Medicaid programs. It’s a bold move to stop Americans from paying tenfold what other nations do. Isn’t it about time we stopped bankrolling the world’s healthcare?
Through the Trump Rx website, launching in January 2026, discounts are staggering—think Sanofi’s blood thinner Plavix dropping from $756 to a mere $16. Novo Nordisk’s Ozempic and Wegovy, both over $1,000 monthly, will fall to $350 each. Eli Lilly’s Zepbound follows suit, down from $1,086 to $346 a month.
Trump didn’t mince words on the disparity: “Whatever the drug sells for… in the world, whatever the lowest number is… we will match that price,” he declared on December 19, 2025. That’s a direct jab at a system that’s fleeced Americans for too long, while progressive policies often ignore the root issue. These agreements mandate that any new drugs from these companies must also carry MFN pricing. It’s a safeguard against future price hikes, and conservatives should cheer this as a win for free-market fairness over unchecked corporate greed.
Beyond domestic relief, Trump is pushing global accountability with an executive order to lower costs here while urging other nations to pay more. The United Kingdom’s National Health Service, for the first time in 26 years, agreed to shoulder a fairer share. If Europe balks, Trump’s ready with tariffs—a tough but necessary stance to protect American wallets.
Trump reflected on past delays, noting the coronavirus pandemic hindered earlier talks with nations like Spain and Italy. Now, with momentum building, he’s not letting up. It’s a pragmatic approach, focusing on timing without bowing to international pressure.
Looking ahead, more deals are on the horizon, including with Johnson & Johnson in the New Year. Trump’s also planning to tackle insurance companies next, aiming to drive their prices down too. This isn’t just a one-off; it’s a sustained fight for affordability.
“This is the biggest thing ever to happen on drug pricing and on health care,” Trump proclaimed on December 19, 2025. And honestly, when you see numbers like Bristol Myers Squibb’s HIV drug Reyataz falling from $1,449 to $217, it’s hard to argue. This isn’t just talk—it’s tangible change for struggling families.
For specific wins, look at EMD Serono’s deal, slashing costs for in vitro fertilization drugs, a boon for couples facing steep medical bills. Or Pfizer’s Eucrisa dropping 80%, with other drugs halved in price. These aren’t abstract promises; they’re real dollars back in Americans’ pockets.
From a conservative lens, this is government doing what it should—protecting citizens from exploitative pricing without overreaching into personal choice. It’s a rejection of the left’s often bloated healthcare fixes, focusing instead on direct, market-driven relief. Let’s keep pushing for transparency to ensure these savings stick.
Ultimately, Trump’s strategy is a populist rallying cry against a system that’s long favored profits over people. With billions in savings projected for State Medicaid programs and everyday buyers, this could reshape healthcare access. The question remains: will other nations step up, or will tariffs force their hand?